EU approves Abbott's Humira for pediatric Crohn's disease

11/28/2012 | PharmaTimes (U.K.)

Abbott Laboratories received approval from the European Commission to market Humira, or adalimumab, for patients ages 6 to 17 with severe active Crohn's disease who don't respond to traditional therapy. The approval marks the ninth time that Humira was cleared in the EU.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC